Back to Search

AMGN

Amgen Inc
Data: 2026-11-12
$468.89
Price
0.41%
Change
$483.99
52W High
$312.39
52W Low
Full AI Analysis Buy/Sell Forecast Trendline Why Moving Charts Options
Analyzing positioning… Options positioning — based on yesterday's biggest open-interest changes See the chart Institutional flows
Track record
signal day → next-day price move
Quick Stats
Nov 12, 2026

38.8

AI Score

AVOID NEW MONEY

0.21

Volume Ratio

TBA

Next Earnings

17

+ve Days (30d)

12

-ve Days (30d)

AMGN Price vs Max Options Open Interest

How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.

AMGN Max Change In Options Open Interest

How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.

AMGN Options - Sort by Max open Interest (near term)

12th November 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

AMGN Daily Out of Money Options - Sort by Max open Interest (near term)

12th November 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

AMGN Daily In the Money Options - Sort by Max open Interest (near term)

12th November 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

AMGN Most Active Options by Volume(near term)

12th November 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track
AMGN Technical Chart Pro Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select an indicator above — it will be added as a pane under the price chart with aligned dates.

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

AMGN Stock Summary

Last updated Nov 12, 2026

AMGN is currently trading at $468.89, positioned above its 200-day moving average of $380.41, indicating a long-term uptrend. The stock has a 52-week range of $312.385 to $483.99.

Technical Analysis: The 50-day moving average stands at $424.93, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 65.528, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.013, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates AMGN at 38.8/100 with a AVOID NEW MONEY recommendation.

AMGN (Amgen Inc) Indicators

Last updated Nov 12, 2026

Indicator Value
RSI(14) 65.528
CMF (20) 0.013
ROC (10) 2.45
ADX (14) 37.65
Indicator Value
MACD (12,26,9) 12.442
AROONOSC (14) 64.286
WILLAMS %R (14) -26.773
MFI (14) 66.489

AMGN Candlestick Patterns

Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.

Date Pattern Signal 5-Day Hit Rate Edge vs Baseline Sample
Nov 06 Counterattack (bullish) (contrarian — textbook says the opposite) Bearish 50.7% +3.7 pts 1054
Nov 05 Marubozu (bearish) (contrarian — textbook says the opposite) Bullish 56.2% +3.2 pts 30540

These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.

Amgen Inc is above both the 50 Day and 200 Day SMA which is considered Bullish.

AMGN Moving Averages Analysis

Amgen Inc has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Nov 12, 2026

Amgen Inc has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Nov 12, 2026

AMGN (Amgen Inc) Simple Moving Averages

Moving Averages are last updated Nov 12, 2026

Days MA
10 466.05
20 454.34
30 440.71
50 424.93
100 409.23
200 380.41

AMGN Fundamental Analysis

P/E (Forward) 19.0476
P/E (Trailing) 26.9699
Market Cap ($) 251.6 billion
Earnings/Share ($) 17.25
Net Profit Margin (%) 0.2414
Dividend/Share ($) 9.94
EPS Estimate Current Year ($) 23.5054
EPS Estimate Next Year ($) 24.9934
WallStreet Target Price ($) 429.74
Most Recent Quarter

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.